Virtu Financial LLC Purchases 22,202 Shares of TransMedics Group, Inc. $TMDX

Virtu Financial LLC grew its position in TransMedics Group, Inc. (NASDAQ:TMDX) by 467.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 26,949 shares of the company’s stock after acquiring an additional 22,202 shares during the quarter. Virtu Financial LLC’s holdings in TransMedics Group were worth $3,278,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Harvest Fund Management Co. Ltd purchased a new position in shares of TransMedics Group during the 3rd quarter worth about $29,000. Allworth Financial LP grew its holdings in TransMedics Group by 74.3% during the 3rd quarter. Allworth Financial LP now owns 265 shares of the company’s stock valued at $30,000 after purchasing an additional 113 shares during the last quarter. Optiver Holding B.V. raised its position in TransMedics Group by 248.1% in the 3rd quarter. Optiver Holding B.V. now owns 268 shares of the company’s stock worth $30,000 after purchasing an additional 191 shares during the period. Parallel Advisors LLC raised its position in TransMedics Group by 42.1% in the 4th quarter. Parallel Advisors LLC now owns 280 shares of the company’s stock worth $34,000 after purchasing an additional 83 shares during the period. Finally, LOM Asset Management Ltd bought a new stake in TransMedics Group in the third quarter worth about $34,000. Institutional investors own 99.67% of the company’s stock.

Insider Activity at TransMedics Group

In other news, Director Thomas J. Gunderson sold 9,624 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $75.06, for a total transaction of $722,377.44. Following the transaction, the director directly owned 16,642 shares of the company’s stock, valued at approximately $1,249,148.52. This trade represents a 36.64% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 6.90% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have issued reports on TMDX. Wall Street Zen lowered TransMedics Group from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. UBS Group reiterated a “hold” rating on shares of TransMedics Group in a report on Tuesday, May 26th. Weiss Ratings reiterated a “hold (c)” rating on shares of TransMedics Group in a report on Tuesday, June 9th. TD Cowen decreased their price target on TransMedics Group from $190.00 to $120.00 and set a “buy” rating for the company in a research note on Wednesday, May 6th. Finally, JPMorgan Chase & Co. boosted their price objective on TransMedics Group from $114.00 to $149.00 and gave the company a “neutral” rating in a report on Wednesday, February 25th. Six equities research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $134.50.

TransMedics Group Trading Up 7.6%

TMDX stock opened at $78.79 on Friday. The company has a market capitalization of $2.72 billion, a PE ratio of 17.91 and a beta of 1.91. TransMedics Group, Inc. has a 12 month low of $60.10 and a 12 month high of $156.00. The firm’s 50-day moving average is $84.00 and its 200 day moving average is $113.03. The company has a debt-to-equity ratio of 1.70, a current ratio of 6.74 and a quick ratio of 6.19.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings data on Tuesday, May 5th. The company reported $0.30 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.62 by ($0.32). The company had revenue of $173.93 million during the quarter, compared to analysts’ expectations of $174.44 million. TransMedics Group had a net margin of 27.04% and a return on equity of 22.38%. TransMedics Group’s quarterly revenue was up 21.2% on a year-over-year basis. During the same period last year, the firm earned $0.70 earnings per share. On average, research analysts anticipate that TransMedics Group, Inc. will post 1.98 EPS for the current year.

TransMedics Group Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.